HROWM Projected Dividend Yield

Sr Nt/Harrow Inc ( NASDAQ : HROWM )

Harrow, Inc. is an eyecare pharmaceutical company. Co. is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns U.S. commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others.

12 YEAR PERFORMANCE RESULTS